DSIP

What is DSIP?

DSIP is a nonapeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, carrying the international nonproprietary name emideltide. It was isolated in 1977 by Marcel Monnier's group in Switzerland from the cerebral venous blood of rabbits whose thalamus had been electrically stimulated into a delta-wave sleep state, and it was named after that EEG signature. It is usually described — including by an earlier version of this page — as a naturally occurring human neuropeptide. That description does not survive the primary literature, and the distinction matters enough to lead with. DSIP-like immunoreactivity is measurable in human cerebrospinal fluid, plasma, urine and milk, but immunoreactivity is antibody cross-reactivity, not molecular identity. DSIP itself has never been isolated and sequenced from human tissue; the 1977 isolation was from rabbit. No DSIP gene has been found, no precursor protein identified, and no receptor cloned or characterised. A 2006 review in the Journal of Neurochemistry put it directly: the sleep link 'has never been further characterized, in part because of the lack of isolation of the DSIP gene, protein and possible related receptor,' and 'its natural occurrence and biological activity still remains obscure.' The same authors hypothesised that a related-but-different peptide, not DSIP, accounts for the measured immunoreactivity. That hypothesis has partial support. A 2011 database analysis searching for a precursor found the closest mammalian homologue in JMJD1B-type histone demethylases, which encode WKGGNASGE — differing from DSIP at two of nine positions. The resulting peptide, KND, was synthesised and reported to have effects comparable to or stronger than DSIP's. There is also a documented precedent for the name misleading people: the so-called 'delta sleep-inducing peptide immunoreactor' turned out to be GILZ, a glucocorticoid-induced leucine zipper transcription factor, an entirely unrelated molecule. So the honest description is a synthetic nonapeptide of rabbit origin with genuine and reproducible biological activity across stress, pain and seizure models, whose endogenous human existence rests on cross-reactive assays, and whose relationship to sleep is the weakest-supported thing about it.

What DSIP Is Investigated For

The DSIP human trial literature splits almost perfectly along a line that is rarely drawn: who ran the study. From the originating group around Schoenenberger and Schneider-Helmert came the positive results. A 1983 series of five double-blind studies reported sleep induction with a one-hour latency but up to twenty hours of duration, 'a complete normalization of disturbed sleep' after four consecutive injections, and improved daytime alertness. A 1987 placebo-controlled study in 14 chronic insomniacs reported sleep efficiency reaching normal-control levels with benefit persisting into the first post-treatment night. From independent groups came the negative ones. Monti and colleagues (1987) ran a double-blind crossover with polysomnography and found no significant differences against baseline or placebo nights, with slow-wave sleep — stages 3 and 4, the delta the peptide is named for — not modified at all; they concluded sleep improvement was 'of little clinical significance.' Bes and colleagues (1992) found the significant effects 'weak and in part could be due to an incidental change in the placebo group' and concluded short-term treatment 'is not likely to be of major therapeutic benefit.' The most recent controlled human study points the other way entirely. In a randomised trial of 24 patients, the 12 who received DSIP as an adjunct to isoflurane anaesthesia — the other 12 got saline — showed a response that ran opposite to the peptide's name: it 'paradoxically, significantly reduced delta rhythm,' increased bispectral index, raised heart rate and lowered heart rate variability — lightening anaesthesia rather than deepening it. The non-sleep applications are, oddly, better supported in direction if not in rigour. Withdrawal protocols for opioids and alcohol produced consistently encouraging open-label results through the 1980s and 1990s; a seven-patient pain pilot reported significant reduction in 6 of 7; stress-axis effects on ACTH and corticosterone are reproducible in animals though inconsistent in humans; and a 2021 rat study found intranasal DSIP improved motor recovery after focal stroke. DSIP is more defensible as a multifunctional stress-adaptive peptide than as a sleep agent — which is precisely the opposite of how it is marketed.

History & Discovery

DSIP was identified in 1977 by Marcel Monnier and his group at the University of Basel, in an experiment that has become part of the lore of sleep neuroscience: stimulating the thalamus of donor rabbits into a delta-wave sleep state, dialysing their cerebral venous blood, and infusing the dialysate into freely moving recipient rabbits, which shifted toward delta-rich sleep. The active fraction was purified and sequenced as a nonapeptide, and named for the EEG signature rather than for any identified target — a naming decision that has shaped expectations ever since. The early excitement was substantial, because the molecular basis of sleep was then almost entirely unknown and DSIP looked like a candidate endogenous sleep regulator. Clinical trials followed through the late 1970s and 1980s in chronic insomnia, narcolepsy, opioid and alcohol withdrawal, chronic pain and stress. Schoenenberger's 1984 review catalogued an extraordinary range of reported activity — circadian effects, interactions with morphine, amphetamine and barbiturates, MAO-A induction, changes during hibernation, altered brain concentrations in alcohol-dependent rats — and also reported the parabolic dose-response and the markedly more potent phosphorylated derivative DSIP-P. The independent replication attempts are what changed the trajectory. Monti's group in Uruguay (1987) and Bes and colleagues in the Netherlands (1992) both ran double-blind polysomnography studies and both concluded the sleep effect was not clinically meaningful. Western pharmaceutical interest faded through the 1990s. The 2009 anaesthesia study, the last controlled human trial, found DSIP reduced delta rhythm. Clinical use did not stop everywhere, and this page previously overstated the case by saying development was effectively discontinued by the late 1990s. Russian work continued around Deltaran, a DSIP-containing preparation positioned for antistress protection, and Ukrainian investigators published small clinical studies of intranasal deltalicin in diabetic retinopathy in 2014 — an indication with no relationship to sleep at all. None of this passed through Western regulatory review. The most interesting recent thread is not about DSIP but about what DSIP might be a proxy for. A 2011 database analysis searching for a biosynthetic precursor found the closest mammalian homologue in JMJD1B-type histone demethylases, encoding WKGGNASGE — two residues different from DSIP. That peptide, named KND, was synthesised and in 2013 reported to have antioxidative, anticonvulsive and behavioural effects 'even more expressed' than DSIP's, and in 2021 was found to reduce both brain infarction and myocardial infarction when given at reperfusion. Forty-nine years after the rabbit experiment, the most promising line of DSIP research concerns a molecule that is not quite DSIP.

How It Works

Nobody knows how DSIP works, and that is not a simplification. It has no known receptor, so there is no target to describe. What the research shows is a peptide that influences several systems at once — stress hormones, pain signalling, seizure threshold — without a single identified point of action. Its effects on sleep, which is what it is named and sold for, are the least reproducible part of the picture.

DSIP is a nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) whose mechanism has resisted characterisation for nearly five decades. The central fact is the absence of a receptor. Two autoradiography studies from 1983 and 1984 reported binding sites for tritiated DSIP on cultured rat brainstem neurons but concluded only that those neurons 'might possess' receptors, and nothing since has cloned, sequenced or pharmacologically characterised one. A 1989 study in the vascularly perfused guinea pig brain described a saturable transport mechanism at the blood-brain barrier with binding at specific capillary membrane sites — relevant to how the peptide gets in, but a transporter rather than a signalling receptor. What has been documented is a scattered set of downstream effects. Electrophysiological work reports effects on pre- and postsynaptic glutamate and postsynaptic GABA receptors in cortex, hippocampus and cerebellum, and separate work implicates NMDA receptors in the response to glutamate microiontophoresis. Stress-axis effects are reproducible in animals — DSIP reduces CRF-induced corticosterone release, and inhibits c-Fos expression in the paraventricular nucleus in a manner blocked by dizocilpine and cycloheximide — while human results are inconsistent, with one study showing reduced immunoreactive ACTH after intravenous injection and others finding no effect on CRH-stimulated or meal-induced ACTH and cortisol, and none on growth hormone or prolactin. An earlier version of this page asserted that DSIP 'has been shown to modulate cortisol and ACTH release' without noting that the page's own citations include two explicitly negative human studies. The sleep mechanism is the weakest link. Beyond the negative independent trials, the 2009 anaesthesia study found DSIP reduced rather than increased delta rhythm in humans. And the 2006 review notes something easy to miss: significant slow-wave-sleep promotion in rabbits and rats was obtained from 'certain artificial DSIP structural analogues (but not DSIP itself!)'. A phosphorylated derivative, DSIP-P, was described by the discovering group as 'manyfold more powerful' than the parent, and a 2018 study found phosphorylated DSIP restored spatial memory and p-CREB expression by improving sleep architecture at high altitude. If the analogues work and the parent does not, the implication is that DSIP may be a weakly active member of a family rather than the active principle itself — which is exactly what the DSIP-like-peptide hypothesis proposes. One pharmacological property deserves emphasis because it inverts normal dosing intuition: the discovering group reported 'a parabolic dose-response curve with different effective optima' across intracerebroventricular, intravenous and subcutaneous routes. Later Russian work found the same pattern in stress models, with 40 µg/kg effective and 360 µg/kg abolishing the effect. There is a window, and exceeding it does not simply plateau.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about DSIP:

• 01Whether DSIP exists endogenously in humans at all. Detection rests on cross-reactive immunoassays; the peptide has never been isolated and sequenced from human tissue, no gene has been found, and the best candidate precursor identified so far encodes a different peptide (WKGGNASGE, differing at two of nine positions).
• 02The receptor. None has been cloned, sequenced or characterised in nearly fifty years. The entire literature is two 1983-84 autoradiography papers concluding neurons 'might possess' binding sites, plus a 1989 blood-brain-barrier transport study.
• 03Why structural analogues outperform the parent. Phosphorylated DSIP was described as 'manyfold more powerful', slow-wave-sleep promotion in rabbits and rats came from analogues 'but not DSIP itself', and the DSIP-like KND peptide showed effects 'even more expressed' than DSIP's. If the analogues are the active species, the entire DSIP literature may be studying the wrong molecule.
• 04Modern replication under current standards. No human trial has been published since 2014 and no controlled sleep trial since 1992. Nothing has been tested against contemporary insomnia diagnostic criteria, modern polysomnographic scoring, or active comparators such as z-drugs or orexin antagonists.
• 05Human pharmacokinetics. Nothing since the 1980s. The best transport data comes from perfused guinea pig brain in 1989. Subcutaneous bioavailability — the route actually used outside trials — has never been characterised in humans.
• 06The parabolic dose-response. Reported repeatedly but never systematically mapped in humans, which makes every dose recommendation circulating online guesswork about where the optimum sits.
• 07What research-chemical DSIP products actually contain. No published analytical study has examined identity, purity or peptide content of commercial preparations, despite this being the only way most people encounter the compound.
• 08The non-sleep indications. Withdrawal, pain and stroke-recovery signals are the more reproducible part of the DSIP literature and have attracted almost no modern follow-up — the opposite of where attention has gone.

Forms & Administration

In published human research, DSIP was given by slow intravenous injection or infusion — older studies stressed that slow injection was essential — with intranasal administration used in the Russian and Ukrainian clinical work (Deltaran, deltalicin) and in the 2021 rat stroke study. Research-chemical-channel material is supplied as lyophilised powder for reconstitution and subcutaneous use, a route with no published human dose-response data behind it. There is no pharmaceutical-grade DSIP product on Western markets and no legitimate compounding pathway.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

DSIP is not approved as a medicine in the United States, the EU, the UK or any other Western jurisdiction, and has no legitimate compounding pathway. It was nominated to the FDA as a bulk drug substance for compounding and then withdrawn from consideration. Material sold online is research-chemical-channel product not authorised for human use.

Timeline of Effects

Monitoring & Measurement

Common Questions

Who DSIP Is NOT For

Drug & Supplement Interactions

Documented clinical interaction data for DSIP does not exist. The human literature is decades old and predates systematic interaction study, and the absence of an identified receptor makes mechanistic prediction unusually unreliable — there is no target at which to reason about competition or synergy. The theoretical concerns are concentrated in two areas. With agents acting on sleep architecture — benzodiazepines, z-drugs such as zolpidem, zopiclone and eszopiclone, and the orexin receptor antagonists suvorexant, lemborexant and daridorexant — DSIP's reported effects on sleep staging could be additive in unpredictable directions, particularly given the 2009 finding that it lightened anaesthetic depth rather than deepening it. That result is worth flagging specifically for anyone combining DSIP with a sedative and assuming the effects will add in the expected direction. With opioids and opioid-replacement therapy, DSIP's documented use in withdrawal protocols and its apparent interaction with endogenous opioid signalling suggest a real pharmacodynamic relationship, though its magnitude alongside chronic agonist therapy is uncharacterised. Schoenenberger's review also reported interactions with morphine, amphetamine and barbiturates in animal work. With corticosteroids and drugs influencing ACTH and cortisol dynamics, a theoretical interaction follows from the reported effects on ACTH and vasopressin secretion — but the human data here are contradictory, with two of this page's own citations finding no effect on CRH-stimulated or meal-induced ACTH and cortisol. No interaction concerns are documented with cardiovascular medications, oral hypoglycaemics or anticoagulants. The absence of documented interactions reflects the age and narrowness of the literature rather than demonstrated safety.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions